Two pathways of carcinogenesis: MSI vs CIN in Iranian patinets with colorectal cancer

被引：0

作者：

Molaei, Mahsa ^{[1
]}

Noorinayer, Babak ^{[1
]}

Ghanbarimotlagh, Ali ^{[1
]}

Emami, S. Alireza ^{[1
]}

Ghiasi, Somaye ^{[1
]}

Zali, Mohamadreza ^{[1
]}

机构：

[1] Shahid Beheshti Univ Med Sci, Res Ctr Gastroenterol & Liver Dis, Tehran, Iran

来源：

AMERICAN JOURNAL OF GASTROENTEROLOGY | 2007年 / 102卷

关键词：

D O I：

10.14309/00000434-200709002-00387

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

387

引用

页码：S257 / S258

页数：2

共 50 条

[41] Clinicopathological factors influencing outcome in metastatic colorectal cancer patients treated with fluoropyrimidine and bevacizumab maintenance treatment vs observation: an individual patient data meta-analysis of two phase 3 trials
Goey, Kaitlyn K. H.
Elias, Sjoerd G.
Hinke, Axel
van Oijen, Martijn G. H.
Punt, Cornelis J. A.
Hegewisch-Becker, Susanna
Arnold, Dirk
Koopman, Miriam
BRITISH JOURNAL OF CANCER, 2017, 117 (12) : 1768 - 1776
[42] A randomized two arm phase III study in patients post radical resection of liver metastases of colorectal cancer to investigate bevacizumab in combination with capecitabine plus oxaliplatin (CAPOX) vs CAPOX alone as adjuvant treatment
Snoeren, Nikol
Voest, Emile E.
Bergman, Andre M.
Dalesio, Otilia
Verheul, Henk M.
Tollenaar, Rob A. E. M.
van der Sijp, Joost R. M.
Schouten, Sander B.
Rinkes, Inne H. M. Borel
van Hillegersberg, R.
BMC CANCER, 2010, 10
[43] A randomized two arm phase III study in patients post radical resection of liver metastases of colorectal cancer to investigate bevacizumab in combination with capecitabine plus oxaliplatin (CAPOX) vs CAPOX alone as adjuvant treatment
Nikol Snoeren
Emile E Voest
Andre M Bergman
Otilia Dalesio
Henk M Verheul
Rob AEM Tollenaar
Joost RM van der Sijp
Sander B Schouten
Inne HM Borel Rinkes
R van Hillegersberg
BMC Cancer, 10
[44] Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): First results of the CheckMate 8HW study
Andre, Thierry
Elez, Elena
Van Cutsem, Eric
Jensen, Lars Henrik
Bennouna, Jaafar
Mendez, Guillermo
Schenker, Michael
De La Fouchardiere, Christelle
Limon, Maria Luisa
Yoshino, Takayuki
Li, Jin
Lenz, Heinz-Josef
Manzano Mozo, Jose Luis
Tortora, Giampaolo
Garcia-Carbonero, Rocio
Cela, Elvis
Yang, Yingsi
Lei, Ming
Jin, Lixian
Lonardi, Sara
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : LBA768 - LBA768
[45] SEAMARK: Randomized phase 2 study of pembrolizumab plus encorafenib plus cetuximab vs pembrolizumab alone for first-line treatment of BRAF V600E-mutant microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) metastatic colorectal cancer (CRC).
Kopetz, Scott
Bekaii-Saab, Tanios S.
Yoshino, Takayuki
Chung, Chin-Hee
Zhang, Xiaosong
Tabernero, Josep
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : TPS268 - TPS268
[46] Health-related quality of life (HRQoL) in patients (pts) treated with pembrolizumab (pembro) vs chemotherapy as first-line treatment in microsatellite instability-high (MSI-H) and/or deficient mismatch repair (dMMR) metastatic colorectal cancer (mCRC): Phase III KEYNOTE-177 study
Andre, T.
Amonkar, M.
Norquist, J.
Shiu, K-K.
Kim, T. W.
Jensen, B. V.
Jensen, L. H.
Punt, C. J.
Smith, D.
Garcia-Carbonero, R.
Sevilla, I.
de la Fouchardiere, C.
Rivera, F.
Elez, E.
Diaz, L. A.
Yoshino, T.
Van Cutsem, E.
Yang, P.
Farooqui, M. Z. H.
Le, D.
ANNALS OF ONCOLOGY, 2020, 31 : S409 - S409
[47] Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Expanded efficacy analysis from CheckMate 8HW
Lenz, Heinz-Josef
Lonardi, Sara
Elez, Elena
Van Cutsem, Eric
Jensen, Lars Henrik
Bennouna, Jaafar
Mendez, Guillermo
Schenker, Michael
De La Fouchardiere, Christelle
Limon, Maria Luisa
Yoshino, Takayuki
Li, Jin
Manzano, Jose Luis
Tortora, Giampaolo
Garcia-Carbonero, Rocio
Joshi, Rohit
Cela, Elvis
Chen, Tian
Jin, Lixian
Andre, Thierry
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[48] Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Subgroup efficacy and expanded safety analyses from CheckMate 8HW
Andre, T.
Lonardi, S.
Lenz, H. J.
Jensen, L. H.
Van Cutsem, E.
Touchefeu, Y.
Garcia-Carbonero, R.
Tougeron, D.
Mendez, G. A.
Schenker, M.
de la Fouchardiere, C.
Limon, M. L.
Yoshino, T.
Li, J.
Manzano Mozo, J. L.
Cela, E.
Chen, T.
Lei, M.
Jin, L.
Elez Fernandez, M. E.
ANNALS OF ONCOLOGY, 2024, 35 : S451 - S452
[49] Nivolumab (NIVO) plus low-dose ipilimumab (IPI) as first-line (1L) therapy in microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Two-year clinical update.
Lenz, Heinz-Josef
Lonardi, Sara
Zagonel, Vittorina
Van Cutsem, Eric
Limon, M. Luisa
Wong, Mark
Hendlisz, Alain
Aglietta, Massimo
Garcia-Alfonso, Pilar
Neyns, Bart
Gelsomino, Fabio
Cardin, Dana Backlund
Dragovich, Tomislav
Shah, Usman
Yang, Jing
Ledeine, Jean-Marie
Overman, Michael J.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[50] Health-related quality of life (HRQoL) with first-line (1L) nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) in patients (pts) with microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): CheckMate 8HW
Lonardi, S.
Andre, T.
Arnold, D.
Garcia-Carbonero, R.
Chalabi, M.
Elez Fernandez, M. E.
Lenz, H. J.
Jensen, L. H.
Joshi, R.
Roodhart, J. M. L.
Yoshino, T.
Dixon, M.
Blum, S. I.
Sims, J.
Lawrance, R.
Taylor, F.
Chen, T.
Cela, E.
Jin, L.
Van Cutsem, E.
ANNALS OF ONCOLOGY, 2024, 35 : S1 - S2

← 1 2 3 4 5 →